On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET), by . PharmaEssentia USA Corporation.
In the SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide for high-risk essential thrombocythemia patients ...
Rusfertide showed a 77% clinical response rate in polycythemia vera patients, significantly higher than the 33% with placebo. The drug reduced phlebotomy frequency, with 0.5 per patient in the ...
The blood you don’t need could be exactly what someone else is praying for. It sounds inconceivable, yet for patients requiring frequent therapeutic phlebotomy—blood removal as treatment—this blood is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results